Verici Dx Plc (LSE:VRCI) — Market Cap & Net Worth
Market Cap & Net Worth: Verici Dx Plc (VRCI)
Verici Dx Plc (LSE:VRCI) has a market capitalization of $69.05K (GBX567.52 Million) as of June 19, 2026. Listed on the LSE stock exchange, this UK-based company holds position #31371 globally and #1174 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Verici Dx Plc's stock price GBX0.38 by its total outstanding shares 1513394127 (1.51 Billion). Review VRCI liabilities breakdown to assess the company's total debt and financial obligations.
Verici Dx Plc Market Cap History: 2020 to 2026
Verici Dx Plc's market capitalization history from 2020 to 2026. Data shows change from $10.77 Million to $69.05K (-55.69% CAGR).
Index Memberships
Verici Dx Plc is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
FTSE AIM All Share Index
FTAI
|
$939.61 Million | 0.01% | #395 of 722 |
Weight: Verici Dx Plc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Verici Dx Plc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Verici Dx Plc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.21x
Verici Dx Plc's market cap is 0.21 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2023 | $1.80 Million | $1.01 Million | -$8.73 Million | 1.77x | N/A |
| 2024 | $713.53K | $3.34 Million | -$5.87 Million | 0.21x | N/A |
Competitor Companies of VRCI by Market Capitalization
Companies near Verici Dx Plc in the global market cap rankings as of June 19, 2026.
Key companies related to Verici Dx Plc by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #131 globally with a market cap of $174.56 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #189 globally with a market cap of $125.14 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #621 globally with a market cap of $44.18 Billion USD.
- LONZA GROUP UNSP.ADR 1/10 (F:LO3A): Ranked #664 globally with a market cap of $41.04 Billion USD ( €35.10 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #131 | Thermo Fisher Scientific Inc | NYSE:TMO | $174.56 Billion | $464.61 |
| #189 | Danaher Corporation | NYSE:DHR | $125.14 Billion | $177.17 |
| #621 | IDEXX Laboratories Inc | NASDAQ:IDXX | $44.18 Billion | $562.09 |
| #664 | LONZA GROUP UNSP.ADR 1/10 | F:LO3A | $41.04 Billion | €54.50 |
Verici Dx Plc Historical Marketcap From 2020 to 2026
Between 2020 and today, Verici Dx Plc's market cap moved from $10.77 Million to $ 69.05K, with a yearly change of -55.69%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | GBX69.05K | -48.28% |
| 2025 | GBX133.50K | -81.29% |
| 2024 | GBX713.53K | -60.26% |
| 2023 | GBX1.80 Million | -22.00% |
| 2022 | GBX2.30 Million | -75.49% |
| 2021 | GBX9.39 Million | -12.82% |
| 2020 | GBX10.77 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 19th, 2026 the market cap of Verici Dx Plc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $69.05K USD |
| MoneyControl | $69.05K USD |
| MarketWatch | $69.05K USD |
| marketcap.company | $69.05K USD |
| Reuters | $69.05K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Verici Dx Plc
Verici Dx plc, together with its subsidiary, Verici Dx Inc, develops prognostic and diagnostic tests for kidney transplant patients in the United Kingdom and the United States. The company develops Tutivia, a post-transplant diagnostic test focused on acute cellular rejection, including sub-clinical rejection; and Protega, a liquid biopsy to predict the risk of fibrosis and long-term graft failur… Read more